Stockscreener 앱 받기
38.88
0.02%
-0.03
전일 마감가:
$38.85
열려 있는:
$39.38
하루 거래량:
355.56K
Relative Volume:
0.36
시가총액:
$3.13B
수익:
-
순이익/손실:
$-153.72M
주가수익비율:
-69.43
EPS:
-0.56
순현금흐름:
$-103.81M
1주 성능:
+9.82%
1개월 성능:
+11.07%
6개월 성능:
+210.74%
1년 성능:
+170.68%
1일 변동 폭
$38.20
$39.58
1주일 범위
$34.51
$39.58
52주 변동 폭
$11.39
$40.13
Verona Pharma Plc Adr Stock (VRNA) Company Profile
명칭
Verona Pharma Plc Adr
전화
011-44-0-2032834200
주소
3 MORE LONDON RIVERSIDE, LONDON
VRNA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| VRNA | 38.88 | 3.13B | 0 | -153.72M | -103.81M | -0.56 |
| VRTX | 448.12 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.89 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.60 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.17 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.72 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Verona Pharma Plc Adr Stock (VRNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-05-22 | 재개 | Jefferies | Buy |
| 2022-09-19 | 재개 | Wedbush | Outperform |
| 2022-08-26 | 개시 | Piper Sandler | Overweight |
| 2021-09-13 | 개시 | H.C. Wainwright | Buy |
| 2020-08-25 | 개시 | Jefferies | Buy |
| 2020-08-10 | 개시 | Canaccord Genuity | Buy |
| 2019-04-18 | 개시 | BTIG Research | Buy |
모두보기
Verona Pharma Plc Adr 주식(VRNA)의 최신 뉴스
Verona Pharma director Christina Ackermann acquires $198,385 in shares - Investing.com
Verona Pharma director David Ebsworth buys $188,880 in shares - Investing.com
Verona Pharma CFO Mark Hahn sells shares worth $568,386 - Investing.com
Earnings call: Verona Pharma reports Q3 results, optimistic on Ohtuvayre By Investing.com - Investing.com Nigeria
Earnings call: Verona Pharma reports Q3 results, optimistic on Ohtuvayre - Investing.com India
Exxon Mobil, Constellation Lead Afternoon Market Cap Stock Movers on Monday - Investing.com Nigeria
Exxon Mobil, Constellation Lead Afternoon Market Cap Stock Movers on Monday By Investing.com - Investing.com South Africa
Verona Pharma ADR earnings matched, revenue topped estimates By Investing.com - Investing.com UK
Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire Inc.
Verona Pharma CFO Mark Hahn sells shares worth $632,760 - Investing.com India
Verona Pharma CEO David Zaccardelli sells shares worth $633,895 - Investing.com India
Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma - Barchart
5 Biotech Stocks Likely To Outperform As Industry Prospects Look Bright - Barchart
Verona Pharma CEO David Zaccardelli sells $2.25 million in shares - Investing.com India
Verona Pharma CEO David Zaccardelli sells $2.25 million in shares By Investing.com - Investing.com South Africa
Verona Pharma CFO Mark Hahn sells shares worth $2.3 million By Investing.com - Investing.com South Africa
Verona Pharma CFO Mark Hahn sells shares worth $2.3 million - Investing.com India
Market Insights: Verona Pharma Plc ADR (VRNA)’s Notable Drop of -0.55, Closing at 34.07 - The Dwinnex
Verona Pharma Plc ADR [VRNA] Insider Activity: An Update for Investors - Knox Daily
Phathom Pharmaceuticals Inc [PHAT] Investment Appeal on the Rise - Knox Daily
Verona Pharma Plc ADR (VRNA) stock: A year of ups and downs - US Post News
VRNA Shares Experience Decline in Value - Knox Daily
Financial Metrics Exploration: Understanding Verona Pharma Plc ADR (VRNA) Through Ratios - The Dwinnex
A stock that deserves closer examination: Verona Pharma Plc ADR (VRNA) - US Post News
Wells Fargo gives an Overweight recommendation for Verona Pharma Plc ADR (VRNA) - Knox Daily
Verona Pharma Plc ADR’s (NASDAQ: VRNA) Stock Forecast: Increase To $38 In A Year - Stocks Register
Prepare Yourself for Liftoff: Verona Pharma Plc ADR (VRNA) - SETE News
Verona Pharma Plc ADR [VRNA] stock for 2,254,320 USD was sold by ZACCARDELLI DAVID - Knox Daily
Harrow (HROW) Surges 8.4%: Is This an Indication of Further Gains? - Yahoo Finance
Cactus Inc [WHD] Records 50-Day SMA of $59.34 - Knox Daily
Verona Pharma stock soars to all-time high of $30.76 By Investing.com - Investing.com South Africa
Piper Sandler maintains Overweight rating on Verona Pharma shares By Investing.com - Investing.com South Africa
Sea Limited Sponsored ADR (SE) Stock Moves -0.17%: What You Should Know - Yahoo Finance
Verona Pharma stock soars to all-time high of $30.76 - Investing.com
VRNA’s Stock Market Adventure: 58.43% YTD Growth Amidst Volatility - The InvestChronicle
Atour Lifestyle Holdings Limited Sponsored ADR (ATAT) Moves 6.2% Higher: Will This Strength Last? - Yahoo Finance
Tesla and Nvidia Lead Afternoon Market Cap Stock Movers on Thursday - Investing.com
MINISO Group Holding Limited Unsponsored ADR (MNSO) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Verona Pharma Plc ADR (VRNA) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Investing in Verona Pharma Plc ADR (VRNA) might be a great opportunity, but the stock is a bit overvalued - US Post News
Upcoming Stock Splits This Week (September 30 to October 4) – Stay Invested - Yahoo Finance
Investing in Verona Pharma Plc ADR (VRNA) Is Getting More Attractive - Knox Daily
Li Auto Inc. Sponsored ADR (LI) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
Verona Pharma's SWOT analysis: stock soars on Ohtuvayre approval, COPD market potential - Investing.com India
Market Momentum Report: Verona Pharma Plc ADR (VRNA)’s Positive Close at 28.76 - The Dwinnex
Verona Pharma's SWOT analysis: stock soars on Ohtuvayre approval, COPD market potential By Investing.com - Investing.com South Africa
Why Sea Limited Sponsored ADR (SE) Dipped More Than Broader Market Today - Yahoo Finance
Verona Pharma Plc ADR [NASDAQ: VRNA] Sees Decrease in Stock Value - Knox Daily
Atour Lifestyle Holdings Limited Sponsored ADR (ATAT) Just Flashed Golden Cross Signal: Do You Buy? - Yahoo Finance
Sea Limited Sponsored ADR (SE) Outperforms Broader Market: What You Need to Know - Yahoo Finance
The growth track for Verona Pharma Plc ADR (VRNA) has changed recently - SETE News
Verona Pharma Plc Adr (VRNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.42%
0.16%
자본화:
|
볼륨(24시간):